Sandostatin LAR Depot — CareFirst (Caremark)
Vasoactive intestinal peptide tumors (VIPomas)
Initial criteria
- Management of symptoms related to hormone hypersecretion of VIPomas
Reauthorization criteria
- Member is experiencing clinical benefit as evidenced by improvement or stabilization in clinical signs and symptoms since initiation of therapy
Approval duration
12 months